Company news

Replimune Group, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

June 2, 2024

Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2024

Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update

May 15, 2024

Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting

April 6, 2024

Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions

March 25, 2024

Replimune to Present at the American Association for Cancer Research Annual Meeting 2024

March 5, 2024

Replimune to Present at Three Upcoming Investor Conferences

March 4, 2024

Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

February 7, 2024

Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 27, 2023

Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers

December 4, 2023

Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research

November 7, 2023

Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update

November 6, 2023

Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunoth...

November 2, 2023

Replimune Announces Appointment of Emily Hill as Chief Financial Officer

September 18, 2023

Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update

August 2, 2023

Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma

July 30, 2023

Replimune Announces Sander Slootweg will Depart from its Board of Directors

July 19, 2023

Replimune Presents Initial RP1 Data from the ARTACUS Clinical Trial at the 2023 American Transplant Congress (ATC) Meeting

June 5, 2023

Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors

June 4, 2023

Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

June 2, 2023

Replimune to Present at the Jefferies Global Healthcare Conference

May 31, 2023

Replimune to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 24, 2023

Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update

May 17, 2023

Replimune to Participate in the Piper Sandler Spring Biopharma Symposium

May 8, 2023

Replimune Reports Fiscal Third Quarter Financial Results and Provides Corporate Update

February 8, 2023

Replimune to Present at the Virtual SVB Securities Global Biopharma Conference

February 6, 2023

Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer

January 3, 2023

Replimune to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 2, 2023

Replimune Announces Pricing of Public Offering

December 7, 2022

Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma

December 6, 2022

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

December 6, 2022

Replimune to Present at the Piper Sandler 34th Annual Healthcare Conference

November 22, 2022

Replimune to Host Virtual Investor Event on December 7, 2022

November 21, 2022

Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update

November 2, 2022

Replimune Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.

October 6, 2022

Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update

August 3, 2022

Replimune Announces the Departure of Jason Rhodes from its Board of Directors

June 2, 2022

Replimune to Present at the Jefferies Healthcare Conference

June 1, 2022

Replimune To Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 25, 2022

Replimune Reports Fiscal Fourth Quarter and Year-Ended 2022 Financial Results and Provides Corporate Update

May 18, 2022

Replimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic Immunotherapies

March 29, 2022

Replimune to Host Virtual Investor Event on March 30, 2022

March 20, 2022

Replimune to Present at the 11th Annual SVB Leerink Global Healthcare Conference

February 10, 2022

Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update

February 2, 2022

Replimune Announces the Departure of Dr. Otello Stampacchia from its Board of Directors

January 30, 2022

Replimune Provides 2021 Year End Review and Overview of Expected 2022 Milestones

January 9, 2022

Replimune to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 3, 2022

Replimune Appoints Christy Oliger to its Board of Directors

December 1, 2021

Replimune Provides Updated Data from RP2 at the 2021 Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

November 11, 2021

Replimune Announces Presentations at the 2021 Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

September 30, 2021

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 9 decks. Every deck is listed under its year.